Saturday, June 01, 2019 8:16:55 PM
Do they really know we have the secret sauce? I know some people on this board do not like to speculate, but here it is anyways...
Anavex began using Cognision in November 2014, to measure and analyze cognitive biomarkers in 32 Alzheimers patients in a Ph2a 273 study in Australia.
In October 2018 Anavex presents 148 week data on these patients at CTAD. Harold Hampel is quoted as saying "we are about to start with a new study, a phase 2b/3 study, this year - it has already been approved"
In December 2018 Cecchi at Cognision files a patent as inventor of a dosage scheme for Anavex 273 (on and off dosing schedule).
Let's stop here. How much data has Cognision seen through the filing of this patent? How much real time data has Anavex and Cognision seen through December 2018? This is NOT a controlled, blinded trial.
In March 2019 the Schizophrenia Consortium is formed with 3 Huge Pharma companies, Anavex, and Cognision. Let's leave out the other small players because that's just noise to distract you.
How much data is available to Anavex and Cognision through March 2019, which is when this good old boys exclusive club was formed?
Also in March 2019, Kaufman presents the same 148 week data that Hampel presented at CTAD 2018, but more than 5 months later.
How much data is available to our CMO on March 29th when he struts to the stage and presents "stale" 148 week data? I mean what's the point of that unless you had ALL of the data available to see through March 29th, that's more than 4 years of data even though you are only presenting 148 weeks of data. If I am Kaufman, and the data past 148 weeks sucks, I am not presenting Sh%&.
You see, the Secret Sauce is predicated on having really good data.
Speaking of good data, In April 2019 Anavex files a patent relating to the therapeutic benefit of 273 in cardiac dysfunction. Where is this data coming from? Missling has been colecting data with Cognision for more than 4 years, why? Because that's what Missling does. Our drug has an impact on many ailments, and cardiac dysfunction is one of those ailments.
The Aussies are benefiting from Anavex 273 well past 148 weeks, and that can be clearly seen in the timeline of events involving Anavex, Cognision, the Consortium, and Walter Kaufman's actions.
The thing is that Cognision is allowing us to see data as it is processed, and the data is so damn good that Consortiums are being formed, world renowned Rett expert Walter Kaufman is leading the parade on stage, Frugal Missling ordering $1M commercial supply of 273, and now Missling is leading workshops and co-paneling close out sessions at a Psychiatric Drug Development Summit that is being spearheaded by Lundbeck, Sage, and Johnson and Johnson?
Ananvex and Cognision go back more than 4 years and NOW is when others want "in" on this precision medicine thing?
Focus on the timeline of events AND the availability of internal readouts by the company and Cognision. It does not take a rocket scientist to figure out that this data changes the GAME.
The peer reviewed paper on the 148 week data is the death blow.
Recent AVXL News
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans • GlobeNewswire Inc. • 01/24/2024 12:30:00 PM
- Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:00:34 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM